These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32653588)

  • 1. The voltage-gated potassium channel K
    Tajti G; Wai DCC; Panyi G; Norton RS
    Biochem Pharmacol; 2020 Nov; 181():114146. PubMed ID: 32653588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating autoimmune disorders with venom-derived peptides.
    Shen B; Cao Z; Li W; Sabatier JM; Wu Y
    Expert Opin Biol Ther; 2017 Sep; 17(9):1065-1075. PubMed ID: 28695745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide blockers of K
    Chandy KG; Norton RS
    Curr Opin Chem Biol; 2017 Jun; 38():97-107. PubMed ID: 28412597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
    Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
    FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voltage-gated potassium channel 1.3: A promising molecular target in multiple disease therapy.
    Cheng S; Jiang D; Lan X; Liu K; Fan C
    Biomed Pharmacother; 2024 Jun; 175():116651. PubMed ID: 38692062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autocrine-Based Selection of Drugs That Target Ion Channels from Combinatorial Venom Peptide Libraries.
    Zhang H; Du M; Xie J; Liu X; Sun J; Wang W; Xin X; Possani LD; Yea K; Lerner RA
    Angew Chem Int Ed Engl; 2016 Aug; 55(32):9306-10. PubMed ID: 27197631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease.
    Han S; Yi H; Yin SJ; Chen ZY; Liu H; Cao ZJ; Wu YL; Li WX
    J Biol Chem; 2008 Jul; 283(27):19058-65. PubMed ID: 18480054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational exchange in the potassium channel blocker ShK.
    Iwakawa N; Baxter NJ; Wai DCC; Fowler NJ; Morales RAV; Sugase K; Norton RS; Williamson MP
    Sci Rep; 2019 Dec; 9(1):19307. PubMed ID: 31848433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venom-derived peptide inhibitors of voltage-gated potassium channels.
    Norton RS; Chandy KG
    Neuropharmacology; 2017 Dec; 127():124-138. PubMed ID: 28689025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation.
    Rashid MH; Heinzelmann G; Huq R; Tajhya RB; Chang SC; Chhabra S; Pennington MW; Beeton C; Norton RS; Kuyucak S
    PLoS One; 2013; 8(11):e78712. PubMed ID: 24244345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Kv1.3 K
    Varga Z; Tajti G; Panyi G
    Biol Futur; 2021 Mar; 72(1):75-83. PubMed ID: 34554500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of the Inhibitory Peptides ShK and HmK with the Voltage-Gated Potassium Channel K
    Sanches K; Prypoten V; Chandy KG; Chalmers DK; Norton RS
    J Chem Inf Model; 2023 May; 63(10):3043-3053. PubMed ID: 37143234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
    Beeton C; Pennington MW; Norton RS
    Inflamm Allergy Drug Targets; 2011 Oct; 10(5):313-21. PubMed ID: 21824083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
    Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
    Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
    Norton RS; Pennington MW; Wulff H
    Curr Med Chem; 2004 Dec; 11(23):3041-52. PubMed ID: 15578998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies.
    Pérez-Verdaguer M; Capera J; Serrano-Novillo C; Estadella I; Sastre D; Felipe A
    Expert Opin Ther Targets; 2016; 20(5):577-91. PubMed ID: 26634786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Kv1.3 blockers for immunosuppression: WO2012155199.
    Nguyen W
    Expert Opin Ther Pat; 2013 Nov; 23(11):1511-6. PubMed ID: 23968576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life.
    Edwards W; Fung-Leung WP; Huang C; Chi E; Wu N; Liu Y; Maher MP; Bonesteel R; Connor J; Fellows R; Garcia E; Lee J; Lu L; Ngo K; Scott B; Zhou H; Swanson RV; Wickenden AD
    J Biol Chem; 2014 Aug; 289(33):22704-22714. PubMed ID: 24939846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment?
    Wang J; Xiang M
    Pharmacotherapy; 2013 May; 33(5):515-28. PubMed ID: 23649812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sea Anemones: Quiet Achievers in the Field of Peptide Toxins.
    Prentis PJ; Pavasovic A; Norton RS
    Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.